Strategic partnerships Secarna is actively expanding through partnerships with Scenic Biotech and Protalix Biotherapeutics to co-develop oligonucleotide therapies, presenting potential collaboration and co-development sales opportunities for related ocular, renal, genetic, and rare disease programs.

AI powered The company emphasizes its AI-powered OligoCreator platform, suggesting opportunities to offer platform-enabled discovery services, computational biology collaborations, and rapid candidate generation for partners seeking accelerated oligonucleotide therapies.

Focused pipeline With over 20 discovery and development programs spanning immuno-oncology, immunology, viral, neurodegenerative and cardiometabolic diseases, there are multiple potential entry points for licensing, research collaborations, or targeted co-development deals aligned to specific disease areas.

Leadership shifts Recent leadership changes, including CEO transition and new scientific advisors, signal a growth phase and openness to strategic partnerships, monetization of IP, and advisory-driven market opportunities for external collaborations and investment.

Geographic and market fit Based in Germany with an active European biopharma focus, Secarna presents cross-border collaboration potential with EU-based biotech and pharma players seeking oligonucleotide approaches, along with potential interest from global firms pursuing rare disease and immunology programs.